Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 9.9% in April

Structure Therapeutics Inc. (NASDAQ:GPCR) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 4,110,000 shares, an increase of 9.9% from the March 31st total of 3,740,000 shares. Approximately 9.9% of the company’s stock are sold short. Based on an average trading volume of 553,100 shares, the days-to-cover ratio is presently 7.4 days.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Thursday, April 18th. Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $85.71.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GPCR. Brandywine Managers LLC grew its stake in shares of Structure Therapeutics by 9.2% during the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after purchasing an additional 1,007 shares during the period. Picton Mahoney Asset Management purchased a new position in shares of Structure Therapeutics during the 3rd quarter valued at approximately $116,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Structure Therapeutics by 208.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock valued at $177,000 after buying an additional 2,939 shares in the last quarter. Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics during the 4th quarter valued at approximately $139,000. Finally, TrueMark Investments LLC lifted its position in shares of Structure Therapeutics by 13.5% during the 1st quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after buying an additional 3,562 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Up 0.3 %

GPCR opened at $39.04 on Tuesday. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02. The firm’s 50-day moving average price is $39.52 and its 200-day moving average price is $47.43. The company has a market cap of $1.82 billion and a P/E ratio of -47.04.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. On average, research analysts anticipate that Structure Therapeutics will post -0.98 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.